<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00621010</url>
  </required_header>
  <id_info>
    <org_study_id>CTS21166-101</org_study_id>
    <nct_id>NCT00621010</nct_id>
  </id_info>
  <brief_title>Safety Study of CTS21166 to Treat Alzheimer Disease</brief_title>
  <acronym>CTS</acronym>
  <official_title>A Phase 1 Single Escalating Dose Study to Assess the Safety and Pharmacokinetics of CTS21166 Administered Intravenously to Healthy Adult Males</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CoMentis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CoMentis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is the first human exposure for the drug candidate CTS21166 in healthy male
      volunteers
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2007</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of single ascending doses of CTS21166 following intravenous administration</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the pharmacokinetics(PK) of CTS21166 and its major metabolites as assessed in plasma</measure>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CTS21166 (ZPQ-21166)</intervention_name>
    <description>Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.
Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion</description>
    <arm_group_label>Cohort</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy adult male &gt; age 21;

          -  non-smoker (minimum 6 months);

        Exclusion Criteria:

          -  History or evidence of clinically significant cardiovascular, pulmonary, hepatic,
             renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic,neurologic,
             psychiatric, oncologic, or allergic (including anaphylactic drug allergies, but
             excluding untreated, asymptomatic, seasonal allergies at time of dosing) disease

          -  History or evidence of intravenous illicit drug use, human immunodeficiency virus
             (HIV), hepatitis B, or hepatitis C;

          -  Participation in another clinical trial within 30 days prior to dosing
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry Hsu, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>CoMentis</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lifetree Clinical Research</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2008</study_first_submitted>
  <study_first_submitted_qc>February 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 22, 2008</study_first_posted>
  <last_update_submitted>July 7, 2008</last_update_submitted>
  <last_update_submitted_qc>July 7, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 9, 2008</last_update_posted>
  <responsible_party>
    <name_title>Henry Hsu, MD</name_title>
    <organization>Comentis, Inc.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

